Should charities fund medical research -- or is that the state's job?

The debate in brief

The UK's charitable medical research sector is one of the largest in the world. Members of the Association of Medical Research Charities (AMRC) collectively spend around 1.7 billion pounds annually on research. Cancer Research UK alone funds around 50% of all publicly funded cancer research in the UK. The British Heart Foundation invests over 100 million pounds a year in cardiovascular research. The Wellcome Trust, with an endowment of approximately 37 billion pounds, is one of the largest non-governmental funders of biomedical research on earth.

This is either a remarkable strength of the UK research system or an extraordinary failure of state provision -- depending on who you ask. Supporters argue that charitable research funders bring independence, risk appetite, patient focus, and long-term commitment that government cannot match. Critics argue that the state has been allowed to underfund medical research because charities fill the gap, and that a system reliant on donor preferences produces a distorted research portfolio that reflects what is fundable rather than what is needed.

Quick takeaways

The arguments

The case for charity-funded research: independence and risk

The most persuasive argument for charitable research funding is independence. Government research funding is subject to political priorities, spending reviews, and institutional conservatism. The Medical Research Council's budget is set through the UKRI allocation process, which is itself subject to HM Treasury decisions. When the government decides that artificial intelligence, clean energy, or pandemic preparedness are priorities, funding follows -- sometimes at the expense of less fashionable areas of biomedical science.

Charitable funders are not immune to fashion, but they are insulated from the political cycle. Cancer Research UK can commit to a twenty-year research programme without worrying that a change of government will redirect its budget. The British Heart Foundation can fund high-risk, early-stage research that might not survive a public funding body's peer review process. The Wellcome Trust can support unconventional researchers and research approaches -- its Discovery Research programme is explicitly designed to fund scientists with bold ideas that might not pass conventional grant committees.

There is also the question of patient engagement. Disease-specific charities fund research in direct response to the needs of patients and families affected by those conditions. This creates a feedback loop between lived experience and research strategy that government funders have historically struggled to replicate. Cancer Research UK's research strategy is informed by patient advisory panels. The MND Association's funding decisions are shaped by people living with motor neurone disease. This is not mere consultation -- it produces research agendas that reflect the priorities of the people most affected.

The case for state funding: equity and rationality

The counter-argument is that reliance on charity produces a research portfolio shaped by donor preferences rather than scientific opportunity or public health need. As documented in the related debate on disease-specific charities, the charitable funding landscape creates a hierarchy in which cancer, cardiovascular disease, and a small number of high-profile conditions receive the lion's share of investment, while liver disease, respiratory disease, rare diseases, and mental health are systematically underfunded.

A fully state-funded research system could, in principle, allocate funding based on disease burden, research opportunity, and expected health impact. The NIHR's mandate is to fund research that addresses the needs of patients and the NHS -- a framework that is at least intended to be equitable. The NIHR's themed calls for research in underfunded areas (mental health, public health, multimorbidity) represent deliberate corrections to the market failures that charity-funded research cannot self-correct.

There is also a sovereignty argument. When charitable funders provide 40-50% of publicly funded medical research, the research system is dependent on the continued willingness and capacity of charities to give. If a major charity experienced a financial shock -- a downturn in legacies, a drop in public donations, an investment loss affecting its endowment -- the research pipeline would be disrupted in ways that government cannot quickly compensate for. Cancer Research UK cut its research budget by around 90 million pounds across two tranches during the COVID-19 pandemic as its retail and fundraising income collapsed. The resulting gap in cancer research funding was not filled by the state.

The pragmatic middle ground

Most people working in UK medical research acknowledge that the mixed funding system, for all its imperfections, produces good science. The UK consistently ranks second globally in research quality and impact, behind only the United States. The charitable sector has funded Nobel Prize-winning work, including the development of monoclonal antibodies (funded by the MRC and charitable sources) and the sequencing of the human genome (partly funded by the Wellcome Trust). The argument is not that charity-funded research is perfect but that it is better than the realistic alternative -- not a hypothetical well-funded state system, but the actual state system, with its constrained budgets and political vulnerabilities.

The practical question is not whether to replace charitable funding with state funding but how to make the mixed system work better. This means better coordination between charitable and public funders to avoid duplication and fill gaps, more transparent data on the total research portfolio by disease area, and honest acknowledgement from government that the UK research system depends on charitable funding and that this dependency carries risks.

The evidence

The AMRC publishes annual data on its members' research expenditure, providing the most comprehensive overview of charitable research spending in the UK by disease area and research type. This data shows the concentration of charitable funding in cancer and cardiovascular research and the relative underfunding of other conditions.

The Wellcome Trust's annual reports detail its research spending by programme area. Its portfolio is global rather than UK-specific, but a significant proportion of its investment supports UK-based researchers and institutions. Wellcome's 2023-24 annual report showed total charitable expenditure of around 1.6 billion pounds.

UKRI's annual reports document public research investment through the Medical Research Council and other research councils. The NIHR publishes data on its research portfolio by disease area and programme type. Together, these sources allow comparison of charitable and public research investment.

The UK Clinical Research Collaboration's Health Research Analysis exercises (the most recent being the 2018 analysis, with updated data expected) provide the most detailed mapping of total UK health research funding across all sources -- charity, government, and industry -- by disease area and research type. These analyses have consistently shown misalignment between research investment and disease burden.

A 2023 analysis in The Lancet examined the UK's research funding landscape and concluded that the charitable sector's contribution was both a "national asset and a structural vulnerability" -- an asset because it increases total research investment and brings distinctive qualities, a vulnerability because it is dependent on forces outside government control.

Current context

The post-pandemic period has underscored both the value and the fragility of charity-funded research. Cancer Research UK's income recovered from its COVID-era low but the organisation has been open about the lasting impact on its research portfolio. Multi-year research grants that were paused or reduced during 2020-21 created a cohort of early-career researchers whose careers were disrupted. The British Heart Foundation similarly reduced its research spending during the pandemic and has rebuilt gradually.

The Wellcome Trust announced a strategic shift in 2020, focusing its funding on three areas -- infectious disease, mental health, and climate and health -- and withdrawing from some areas it had previously supported. This strategic narrowing illustrated both the independence of charitable funders (Wellcome made a choice no government funder could) and the disruption that strategic shifts by a major funder can cause to researchers in defunded areas.

The government's 2025 Spending Review maintained UKRI's budget in real terms but did not increase it. The NIHR budget was similarly held. In the absence of significant new public investment, the UK's dependence on charitable research funding is likely to persist or increase. The R&D spending target of 2.4% of GDP by 2030 remains government policy but is widely considered unlikely to be met on current trajectories.

Last updated: April 2026

What this means for charities

Medical research charities occupy a peculiar position: they fund what is arguably a core state function, but they do so with a freedom and focus that the state cannot easily replicate. This position carries both power and responsibility.

The power is real. When Cancer Research UK decides to invest in immunotherapy research or the British Heart Foundation prioritises regenerative medicine, they shape the direction of UK science. Their funding decisions determine which early-career researchers get their start, which clinical trials proceed, and which diseases receive the attention of the country's best scientists.

The responsibility is equally real. Research charities should be transparent about what they fund and why, and honest about the gaps their funding model creates. The AMRC has made progress on collective transparency, but the sector has not yet produced a comprehensive, publicly accessible map of total charitable research investment by disease area -- a tool that would allow donors, policymakers, and the public to see clearly where charitable funding flows and where it does not.

For the sector more broadly, the charity-funded research model illustrates a wider truth: charities are most powerful when they complement the state rather than substitute for it, and most vulnerable when the state begins to treat charitable provision as a reason not to invest.

Common questions

Why does the UK rely on charities for research more than other countries?

Historical path dependency. The UK's medical research charity sector developed early and grew large. The Medical Research Council, established in 1913, was one of the first government research funding bodies, but charitable organisations -- particularly cancer charities and later the Wellcome Trust -- grew alongside it rather than being displaced by it. In the United States, the National Institutes of Health (NIH) has a budget of approximately 47 billion dollars, dwarfing US medical charities. In Germany, the state and industry fund the vast majority of medical research. The UK's balance is unusual rather than inevitable.

What happens if a major research charity cuts its funding?

The effects ripple through the research system. When Cancer Research UK reduced its research budget during COVID-19, laboratories closed, postdoctoral positions were not renewed, and clinical trials were delayed. The state did not compensate for the shortfall. Similar disruptions occurred when the Wellcome Trust narrowed its strategic focus. Early-career researchers are particularly vulnerable because their positions are often funded by time-limited charitable grants.

Do charitable funders coordinate with government?

To some extent. The Office for Strategic Coordination of Health Research (OSCHR) was established to coordinate the MRC and the NIHR, and the AMRC engages with government on research priorities. But coordination between charitable and public funders is imperfect. There is no mechanism to ensure that the combined charitable and public research portfolio is optimally allocated, and individual charities make independent funding decisions based on their own strategies.

Is charitable research funding efficient?

AMRC members commit to a set of research governance standards, including independent peer review of funding decisions, transparent reporting, and open access publication of results. The evidence suggests that charitable research funding is generally well-managed and produces high-quality science. The efficiency question is less about individual grants and more about the system: whether the total portfolio of charitable research investment is directed at the areas of greatest need and opportunity.

Could the government replace charitable research funding?

In principle, yes. The additional 1.7 billion pounds in public research funding needed to replace AMRC members' contribution would represent a significant but not impossible increase in the UKRI and NIHR budgets. In practice, no UK government has proposed this. The political appetite for a multi-billion-pound increase in public research spending is limited, particularly when charities continue to fund the work. The familiar dynamic applies: charitable provision reduces political pressure for state investment.

What about industry funding of research?

The pharmaceutical and biotech industries fund substantial medical research in the UK, but their investment is driven by commercial returns rather than public health priorities. Industry research focuses on conditions where profitable treatments can be developed and marketed, which creates its own set of biases. The charity and public sectors fund the basic and translational research that industry then builds upon -- the early-stage, high-risk work that is not commercially viable. This division of labour is broadly functional but depends on each sector fulfilling its role.

Key sources and further reading

• AMRC Annual Research Expenditure Data -- Association of Medical Research Charities. The primary source for charitable medical research spending in the UK, broken down by disease area and research type.

• Wellcome Trust Annual Report and Financial Statements -- Wellcome Trust. Detailed data on the Trust's research spending, strategic priorities, and endowment performance.

• Cancer Research UK Annual Report -- Cancer Research UK. Includes data on research expenditure, income sources, and the proportion of UK cancer research funded by the charity.

• UK Clinical Research Collaboration Health Research Analysis -- UKCRC. The most comprehensive mapping of UK health research funding across all sources, enabling comparison of investment by disease area.

• NIHR Annual Reports -- National Institute for Health and Care Research. Data on publicly funded health research by programme area and disease focus.

• "Charitable Research Funding in the UK: National Asset or Structural Vulnerability?" -- The Lancet, 2023. Analysis of the UK's reliance on charitable research funding and the risks and benefits of the mixed funding model.

• UKRI Annual Reports -- UK Research and Innovation. Data on public research investment including the Medical Research Council's budget and programme spending.

• British Heart Foundation Research Strategy -- British Heart Foundation. The BHF's priorities for cardiovascular research investment, including detail on high-risk and translational funding programmes.